Tags

Type your tag names separated by a space and hit enter

Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Eur J Haematol. 2015 May; 94(5):449-55.EJ

Abstract

This retrospective study considered the outcomes of 181 patients with acute myeloid leukemia (AML) transplanted in second complete remission (CR2) between January 2005 and April 2012 and who received either a myeloablative autologous stem cell transplant (Auto-SCT; n = 82; median age: 48 years; median follow-up: 45 months) or an umbilical cord blood (UCB) allogeneic SCT (n = 99, median age: 46 years; median follow-up: 36 months; conditioning regimens: myeloablative n = 21, reduced n = 78; single unit n = 37, double units n = 62). Although the Auto group showed a significant better prognostic profile at transplant, with longer median interval between diagnosis and time of graft, higher incidence of good-risk cytogenetics and lower number of previously transplanted patients, 3-year OS and LFS were similar between both groups (Auto: 59 ± 6% vs. 50 ± 6%, P = 0.45; and 57 ± 6% vs. 46 ± 6%, P = 0.37). In multivariate analysis, UCB allo-SCT was associated with lower relapse incidence (HR: 0.3, 95% CI: 0.11-0.82, P = 0.02), but higher non-relapse mortality (NRM) (HR: 4.16; 95% CI: 1.46-11.9, P = 0.008). Results from this large study suggest that UCB allo-SCT provides better disease control than auto-SCT, which is especially important in the setting of high-risk disease. However, this disease control advantage is counterbalanced by higher toxicity, highlighting the need for novel approaches aiming to decrease NRM after UCB allo-SCT.

Authors+Show Affiliations

Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie (CI2C), Université de Nantes and INSERM CRNCA UMR 892, Nantes, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

25238651

Citation

Chevallier, Patrice, et al. "Comparison of Umbilical Cord Blood Allogeneic Stem Cell Transplantation Vs. auto-SCT for Adult Acute Myeloid Leukemia Patients in Second Complete Remission at Transplant: a Retrospective Study On Behalf of the SFGM-TC." European Journal of Haematology, vol. 94, no. 5, 2015, pp. 449-55.
Chevallier P, Labopin M, Socie G, et al. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Eur J Haematol. 2015;94(5):449-55.
Chevallier, P., Labopin, M., Socie, G., Rubio, M. T., Blaise, D., Vigouroux, S., Huynh, A., Michallet, M., Bay, J. O., Maury, S., Yakoub-Agha, I., Fegueux, N., Deconinck, E., Contentin, N., Maillard, N., Bulabois, C. E., Francois, S., Oumedaly, R., Raus, N., & Mohty, M. (2015). Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. European Journal of Haematology, 94(5), 449-55. https://doi.org/10.1111/ejh.12451
Chevallier P, et al. Comparison of Umbilical Cord Blood Allogeneic Stem Cell Transplantation Vs. auto-SCT for Adult Acute Myeloid Leukemia Patients in Second Complete Remission at Transplant: a Retrospective Study On Behalf of the SFGM-TC. Eur J Haematol. 2015;94(5):449-55. PubMed PMID: 25238651.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. AU - Chevallier,Patrice, AU - Labopin,Myriam, AU - Socie,Gerard, AU - Rubio,Marie-There, AU - Blaise,Didier, AU - Vigouroux,Stephane, AU - Huynh,Anne, AU - Michallet,Mauricette, AU - Bay,Jacques-Olivier, AU - Maury,Sébastien, AU - Yakoub-Agha,Ibrahim, AU - Fegueux,Nathalie, AU - Deconinck,Eric, AU - Contentin,Nathalie, AU - Maillard,Natacha, AU - Bulabois,Claude-Eric, AU - Francois,Sylvie, AU - Oumedaly,Reman, AU - Raus,Nicole, AU - Mohty,Mohamad, Y1 - 2014/10/13/ PY - 2014/09/12/accepted PY - 2014/9/20/entrez PY - 2014/9/23/pubmed PY - 2015/12/22/medline KW - SFGM-TC KW - acute myeloid leukemia KW - autologous stem cell transplant KW - second complete remission KW - umbilical cord blood allogeneic stem cell transplantation SP - 449 EP - 55 JF - European journal of haematology JO - Eur J Haematol VL - 94 IS - 5 N2 - This retrospective study considered the outcomes of 181 patients with acute myeloid leukemia (AML) transplanted in second complete remission (CR2) between January 2005 and April 2012 and who received either a myeloablative autologous stem cell transplant (Auto-SCT; n = 82; median age: 48 years; median follow-up: 45 months) or an umbilical cord blood (UCB) allogeneic SCT (n = 99, median age: 46 years; median follow-up: 36 months; conditioning regimens: myeloablative n = 21, reduced n = 78; single unit n = 37, double units n = 62). Although the Auto group showed a significant better prognostic profile at transplant, with longer median interval between diagnosis and time of graft, higher incidence of good-risk cytogenetics and lower number of previously transplanted patients, 3-year OS and LFS were similar between both groups (Auto: 59 ± 6% vs. 50 ± 6%, P = 0.45; and 57 ± 6% vs. 46 ± 6%, P = 0.37). In multivariate analysis, UCB allo-SCT was associated with lower relapse incidence (HR: 0.3, 95% CI: 0.11-0.82, P = 0.02), but higher non-relapse mortality (NRM) (HR: 4.16; 95% CI: 1.46-11.9, P = 0.008). Results from this large study suggest that UCB allo-SCT provides better disease control than auto-SCT, which is especially important in the setting of high-risk disease. However, this disease control advantage is counterbalanced by higher toxicity, highlighting the need for novel approaches aiming to decrease NRM after UCB allo-SCT. SN - 1600-0609 UR - https://www.unboundmedicine.com/medline/citation/25238651/Comparison_of_umbilical_cord_blood_allogeneic_stem_cell_transplantation_vs__auto_SCT_for_adult_acute_myeloid_leukemia_patients_in_second_complete_remission_at_transplant:_a_retrospective_study_on_behalf_of_the_SFGM_TC_ L2 - https://doi.org/10.1111/ejh.12451 DB - PRIME DP - Unbound Medicine ER -